Neuropathy News and Research

RSS

Gene therapy for degenerative retinal disease has no safety concerns but fails to improve vision loss

A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries visual signals from the light-sensing retina to the brain.

1 Jun 2022

Easy-to-use foot exercise device to treat sporting injuries and foot complications

A disruptive new device which is designed to build strength in the muscles of the feet, including the intrinsic muscles inside the foot, is set to launch following an injection of specialist support from Heriot-Watt University.

26 May 2022

Medication, lifestyle intervention effective in preventing Type 2 diabetes, but not cardiovascular disease

A lifestyle intervention program of increased physical activity, healthy eating and aiming for weight loss of 7% or more, or taking the medication metformin were effective long-term to delay or prevent Type 2 diabetes in adults with prediabetes.

23 May 2022

NIH team documents various types of neuropathy after COVID vaccination

In a recent study posted to the medRxiv* preprint server, researchers investigated if coronavirus disease 2019 (COVID-19) vaccination could result in neuropathic symptoms.

19 May 2022

Research describes how DNA damage can affect neural health and function

A new research paper in the journal EMBO Reports describes how DNA damage can affect neural health and function.

12 May 2022

New Clinical Practice Resource released to guide the treatment of patients with hearing loss

The American College of Medical Genetics and Genomics has released a new Clinical Practice Resource that will help direct the treatment of patients with hearing loss: "Clinical Evaluation and Etiologic Diagnosis of Hearing Loss: A Clinical Practice Resource of the American College of Medical Genetics and Genomics."

10 May 2022

Gene therapy effectively reduces neuropathic pain in mice with spinal cord injuries

An international team of researchers, led by scientists at University of California San Diego School of Medicine, report that a gene therapy that inhibits targeted nerve cell signaling effectively reduced neuropathic pain with no detectable side effects in mice with spinal cord or peripheral nerve injuries.

9 May 2022

Exploring vitamin D and acute COVID-19 infection

Researchers assessed the presence of vitamin D deficiency in COVID-19-recovered patients

6 May 2022

Researchers develop new platform capable of mitochondrial DNA editing

Researchers from the Center for Genome Engineering within the Institute for Basic Science developed a new gene-editing platform called transcription activator-like effector-linked deaminases, or TALED.

25 Apr 2022

Scientists create a bioengineered 3D model that mimics the biology of two rare neuromuscular diseases

A scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases.

19 Apr 2022

The involvement of the skeletal muscles in long COVID-19

Researchers reviewed the mechanisms of muscle tissue injury, aggravating conditions, and associated sequelae in long COVID‐19.

18 Apr 2022

Dietary influences on long COVID in children

A new study discusses possible mechanisms of long COVID in children and how they might relate to their dietary intake of important vitamins and elements.

13 Apr 2022

Impact of cardiovascular disease in pregnant or postpartum COVID-19 patients

In a recent study posted to the medRxiv* preprint server, researchers reported coronavirus disease 2019 (COVID-19) prognosis worsened by the presence of cardiovascular diseases (CVDs) in pregnant and postpartum women.

11 Apr 2022

One year after severe COVID-19, T cells persist against SARS-CoV-2

In a recently published article in the journal eBioMedicine, scientists have demonstrated that critically ill coronavirus disease 2019 (COVID-19) patients are capable of generating durable memory T cell response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for more than one year after hospital discharge.

28 Mar 2022

SARS-CoV-2 virus may have lingering effects on peripheral nerves

Adding to a growing body of evidence that, for many, problems related to COVID-19 linger longer than the initial infection, researchers at Washington University School of Medicine in St. Louis have found that some people infected during the pandemic's early months experienced peripheral neuropathy - pain, tingling and numbness in the hands and feet - during and following their bouts with the virus.

25 Mar 2022

Bibliographic review evaluates risk of Guillain-Barré syndrome after receiving COVID vaccination

Since the very beginning of the pandemic, there has been concern about the emergence of Guillain-Barré syndrome, a rare disorder where the body's immune system damages nerves. In some cases, nerve damage causes muscle weakness and paralysis.

16 Mar 2022

‘Injections, injections, injections’: Troubling questions follow closure of sprawling pain clinic chain

On May 13 of last year, the cellphones of thousands of California residents undergoing treatment for chronic pain lit up with a terse text message: "Due to unforeseen circumstances, Lags Medical Centers will be closing effective May 19, 2021."

22 Feb 2022

Looking into the long-COVID brain

Neurological issues, ranging from memory lapses to trouble with attention, have been widely reported after recovery from severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection. Unfortunately, there is limited information about pathways to recovery after severe COVID hospitalization. Now, a prospective study of 4,491 patients hospitalized with COVID suggests neurological recovery can take at least a year. The study is currently available on the medRxiv* preprint while awaiting peer review.

13 Feb 2022

Alkem signs license agreement with Harvard to develop, commercialize new technology for treating ischemic conditions

Alkem Laboratories Limited, an Indian multinational pharmaceutical company, has signed a license agreement with Harvard University's Office of Technology Development enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.

11 Feb 2022

Study shows inequalities in addressing post-acute neurological manifestations of COVID-19

Researchers have explored the inequities in understanding and addressing the neurological complications of COVID-19 among marginalized communities in the United States.

19 Jan 2022